Abstract
Introduction: Administration of butyrate enemas might improve the health status of patients with inflammatory bowel disease (IBD). However, the results seem equivocal. Therefore, this systematic review aimed to assess the effect of sodium butyrate enemas on disease activity index (DAI), endoscopic scores, as well as histological and inflammatory parameters in IBD patients. Methods: The PubMed, Scopus, Web of Science, and Cochrane databases were searched. Randomised controlled trials published in English that assessed the effect of butyrate enemas on DAI, clinical symptoms, inflammatory markers, as well as histological and endoscopic scores in patients with Crohn’s disease (CD) and ulcerative colitis (UC) were included in the analysis. Results: Eight studies involving 227 UC patients were included in this analysis. Only one study reported significant differences in DAI between groups. Besides, butyrate treatment groups did not differ significantly from controls concerning the effect on endoscopic and histological scores. Moreover, butyrate enemas exerted a significant effect on few inflammatory parameters measured in colonic mucosal biopsies. Conclusion: The current evidence is limited and does not support the application of butyrate enemas in UC. There are no reliable data regarding the efficacy of butyrate enemas in CD. The systematic review protocol was registered in the PROSPERO database (CRD42020163654).
References
1.
Ng
SC
, Shi
HY
, Hamidi
N
, Underwood
FE
, Tang
W
, Benchimol
EI
, et al Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
. Lancet
. 2018
Dec
;390
(10114
):2769
–78
.
[PubMed]
0140-67362.
Assisi
RF
; GISDI Study Group
. Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity. Results of a multicentre pilot study
. Minerva Gastroenterol Dietol
. 2008
Sep
;54
(3
):231
–8
.
[PubMed]
1121-421X3.
Scheppach
W
, Sommer
H
, Kirchner
T
, Paganelli
GM
, Bartram
P
, Christl
S
, et al Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis
. Gastroenterology
. 1992
Jul
;103
(1
):51
–6
.
[PubMed]
0016-50854.
Scheppach
W
, Weiler
F
. The butyrate story: old wine in new bottles?
Curr Opin Clin Nutr Metab Care
. 2004
Sep
;7
(5
):563
–7
.
[PubMed]
1363-19505.
Hamer
HM
, Jonkers
DM
, Renes
IB
, Vanhoutvin
SA
, Kodde
A
, Troost
FJ
, et al Butyrate enemas do not affect human colonic MUC2 and TFF3 expression
. Eur J Gastroenterol Hepatol
. 2010
Sep
;22
(9
):1134
–40
.
[PubMed]
0954-691X6.
Hamer
HM
, Jonkers
DM
, Vanhoutvin
SA
, Troost
FJ
, Rijkers
G
, de Bruïne
A
, et al Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission
. Clin Nutr
. 2010
Dec
;29
(6
):738
–44
.
[PubMed]
0261-56147.
Vernia
P
, Cittadini
M
, Caprilli
R
, Torsoli
A
. Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate
. Dig Dis Sci
. 1995
Feb
;40
(2
):305
–7
.
[PubMed]
0163-21168.
Steinhart
AH
, Hiruki
T
, Brzezinski
A
, Baker
JP
. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial
. Aliment Pharmacol Ther
. 1996
Oct
;10
(5
):729
–36
.
[PubMed]
0269-28139.
Di Sabatino
A
, Morera
R
, Ciccocioppo
R
, Cazzola
P
, Gotti
S
, Tinozzi
FP
, et al Oral butyrate for mildly to moderately active Crohn’s disease
. Aliment Pharmacol Ther
. 2005
Nov
;22
(9
):789
–94
.
[PubMed]
0269-281310.
Di Sabatino
A
, Cazzola
P
, Ciccocioppo
R
, Morera
R
, Biancheri
P
, Rovedatti
L
, et al Efficacy of butyrate in the treatment of mild to moderate Crohn’s disease
. Dig Liver Dis Suppl.
2007
Sep
;1
(1
):31
–5
. 11.
Vernia
P
, Annese
V
, Bresci
G
, d’Albasio
G
, D’Incà
R
, Giaccari
S
, et al; Gruppo Italiano per lo Studio del Colon and del Retto
. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial
. Eur J Clin Invest
. 2003
Mar
;33
(3
):244
–8
.
[PubMed]
0014-297212.
Lührs
H
, Gerke
T
, Müller
JG
, Melcher
R
, Schauber
J
, Boxberge
F
, et al Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis
. Scand J Gastroenterol
. 2002
Apr
;37
(4
):458
–66
.
[PubMed]
0036-552113.
Vernia
P
, Monteleone
G
, Grandinetti
G
, Villotti
G
, Di Giulio
E
, Frieri
G
, et al Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study
. Dig Dis Sci
. 2000
May
;45
(5
):976
–81
.
[PubMed]
0163-211614.
Scheppach
W
, Müller
JG
, Boxberger
F
, Dusel
G
, Richter
F
, Bartram
HP
, et al Histological changes in the colonic mucosa following irrigation with short-chain fatty acids
. Eur J Gastroenterol Hepatol
. 1997
Feb
;9
(2
):163
–8
.
[PubMed]
0954-691X15.
Scheppach
W
; German-Austrian SCFA Study Group
. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial
. Dig Dis Sci
. 1996
Nov
;41
(11
):2254
–9
.
[PubMed]
0163-211616.
Steinhart
AH
, Brzezinski
A
, Baker
JP
. Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas
. Am J Gastroenterol
. 1994
Feb
;89
(2
):179
–83
.
[PubMed]
0002-927017.
Moher
D
, Liberati
A
, Tetzlaff
J
, Altman
DG
; PRISMA Group
. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
. PLoS Med
. 2009
Jul
;6
(7
):e1000097
.
[PubMed]
1549-127718.
Higgins
JP
, Thomas
J
, Chandler
J
, Cumpston
M
, Li
T
, Page
MJ
, et al Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane; 2019
. Available from: www.training.cochrane.org/handbook19.
Higgins
JP
, Altman
DG
, Gøtzsche
PC
, Jüni
P
, Moher
D
, Oxman
AD
, et al; Cochrane Bias Methods Group
; Cochrane Statistical Methods Group
. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
. BMJ
. 2011
Oct
;343
oct18 2
:d5928
.
[PubMed]
0959-813820.
van der Heide
H
, van den Brandt-Gradel
V
, Tytgat
GN
, Endert
E
, Wiltink
EH
, Schipper
ME
, et al Comparison of beclomethasone dipropionate and prednisolone 21-phosphate enemas in the treatment of ulcerative proctitis
. J Clin Gastroenterol
. 1988
Apr
;10
(2
):169
–72
.
[PubMed]
0192-079021.
Harig
JM
, Soergel
KH
, Komorowski
RA
, Wood
CM
. Treatment of diversion colitis with short-chain-fatty acid irrigation
. N Engl J Med
. 1989
Jan
;320
(1
):23
–8
.
[PubMed]
0028-479322.
Riley
SA
, Mani
V
, Goodman
MJ
, Herd
ME
, Dutt
S
, Turnberg
LA
. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis
. Gastroenterology
. 1988
Jun
;94
(6
):1383
–9
.
[PubMed]
0016-508523.
Saverymuttu
SH
, Camilleri
M
, Rees
H
, Lavender
JP
, Hodgson
HJ
, Chadwick
VS
. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion
. Gastroenterology
. 1986
May
;90
(5 Pt 1
):1121
–8
.
[PubMed]
0016-508524.
Vanhoutvin
SA
, Troost
FJ
, Hamer
HM
, Lindsey
PJ
, Koek
GH
, Jonkers
DM
, et al Butyrate-induced transcriptional changes in human colonic mucosa
. PLoS One
. 2009
Aug
;4
(8
):e6759
.
[PubMed]
1932-620325.
Säemann
MD
, Böhmig
GA
, Osterreicher
CH
, Burtscher
H
, Parolini
O
, Diakos
C
, et al Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production
. FASEB J
. 2000
Dec
;14
(15
):2380
–2
.
[PubMed]
0892-663826.
Fusunyan
RD
, Quinn
JJ
, Ohno
Y
, MacDermott
RP
, Sanderson
IR
. Butyrate enhances interleukin (IL)-8 secretion by intestinal epithelial cells in response to IL-1beta and lipopolysaccharide
. Pediatr Res
. 1998
Jan
;43
(1
):84
–90
.
[PubMed]
0031-399827.
Gibson
P
, Rosella
O
. Interleukin 8 secretion by colonic crypt cells in vitro: response to injury suppressed by butyrate and enhanced in inflammatory bowel disease
. Gut
. 1995
Oct
;37
(4
):536
–43
.
[PubMed]
0017-574928.
Malago
JJ
, Koninkx
JF
, Tooten
PC
, van Liere
EA
, van Dijk
JE
. Anti-inflammatory properties of heat shock protein 70 and butyrate on Salmonella-induced interleukin-8 secretion in enterocyte-like Caco-2 cells
. Clin Exp Immunol
. 2005
Jul
;141
(1
):62
–71
.
[PubMed]
0009-910429.
Weng
M
, Walker
WA
, Sanderson
IR
. Butyrate regulates the expression of pathogen-triggered IL-8 in intestinal epithelia
. Pediatr Res
. 2007
Nov
;62
(5
):542
–6
.
[PubMed]
0031-399830.
Bakker-Zierikzee
AM
, Tol
EA
, Kroes
H
, Alles
MS
, Kok
FJ
, Bindels
JG
. Faecal SIgA secretion in infants fed on pre- or probiotic infant formula
. Pediatr Allergy Immunol
. 2006
Mar
;17
(2
):134
–40
.
[PubMed]
0905-615731.
Roediger
WE
. The colonic epithelium in ulcerative colitis: an energy-deficiency disease?
Lancet
. 1980
Oct
;2
(8197
):712
–5
.
[PubMed]
0140-673632.
Den Hond
E
, Hiele
M
, Evenepoel
P
, Peeters
M
, Ghoos
Y
, Rutgeerts
P
. In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis
. Gastroenterology
. 1998
Sep
;115
(3
):584
–90
.
[PubMed]
0016-508533.
Facchin
S
, Vitulo
N
, Calgaro
M
, Buda
A
, Romualdi
C
, Pohl
D
, et al Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease
. Neurogastroenterol Motil
. 2020
Oct
;32
(10
):e13914
.
[PubMed]
1350-192534.
Chen
L
, Sun
M
, Wu
W
, Yang
W
, Huang
X
, Xiao
Y
, et al Microbiota metabolite butyrate differentially regulates Th1 and Th17 cells’ differentiation and function in induction of colitis
. Inflamm Bowel Dis
. 2019
Aug
;25
(9
):1450
–61
.
[PubMed]
1078-099835.
Wang
B
, Morinobu
A
, Horiuchi
M
, Liu
J
, Kumagai
S
. Butyrate inhibits functional differentiation of human monocyte-derived dendritic cells
. Cell Immunol
. 2008
May-Jun
;253
(1-2
):54
–8
.
[PubMed]
0008-874936.
Nastasi
C
, Fredholm
S
, Willerslev-Olsen
A
, Hansen
M
, Bonefeld
CM
, Geisler
C
, et al Butyrate and propionate inhibit antigen-specific CD8+ T cell activation by suppressing IL-12 production by antigen-presenting cells
. Sci Rep
. 2017
Nov
;7
(1
):14516
.
[PubMed]
2045-232237.
Qiang
Y
, Xu
J
, Yan
C
, Jin
H
, Xiao
T
, Yan
N
, et al Butyrate and retinoic acid imprint mucosal-like dendritic cell development synergistically from bone marrow cells
. Clin Exp Immunol
. 2017
Sep
;189
(3
):290
–7
.
[PubMed]
0009-910438.
Fernando
MR
, Saxena
A
, Reyes
JL
, McKay
DM
. Butyrate enhances antibacterial effects while suppressing other features of alternative activation in IL-4-induced macrophages
. Am J Physiol Gastrointest Liver Physiol
. 2016
May
;310
(10
):G822
–31
.
[PubMed]
0193-185739.
Zimmerman
MA
, Singh
N
, Martin
PM
, Thangaraju
M
, Ganapathy
V
, Waller
JL
, et al Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells
. Am J Physiol Gastrointest Liver Physiol
. 2012
Jun
;302
(12
):G1405
–15
.
[PubMed]
0193-185740.
Kespohl
M
, Vachharajani
N
, Luu
M
, Harb
H
, Pautz
S
, Wolff
S
, et al The microbial metabolite butyrate induces expression of Th1-associated factors in CD4+ T cells
. Front Immunol
. 2017
Aug
;8
:1036
.
[PubMed]
1664-322441.
Sałkowska
A
, Karaś
K
, Walczak-Drzewiecka
A
, Dastych
J
, Ratajewski
M
. Differentiation stage-specific effect of histone deacetylase inhibitors on the expression of RORγT in human lymphocytes
. J Leukoc Biol
. 2017
Dec
;102
(6
):1487
–95
.
[PubMed]
0741-540042.
Singh
V
, Yeoh
BS
, Walker
RE
, Xiao
X
, Saha
P
, Golonka
RM
, et al Microbiota fermentation-NLRP3 axis shapes the impact of dietary fibres on intestinal inflammation
. Gut
. 2019
Oct
;68
(10
):1801
–12
.
[PubMed]
0017-574943.
Vancamelbeke
M
, Laeremans
T
, Vanhove
W
, Arnauts
K
, Ramalho
AS
, Farré
R
, et al Butyrate does not protect against inflammation-induced loss of epithelial barrier function and cytokine production in primary cell monolayers from patients with ulcerative colitis
. J Crohn’s Colitis
. 2019
Sep
;13
(10
):1351
–61
.
[PubMed]
1873-994644.
Aden
K
, Rehman
A
, Waschina
S
, Pan
WH
, Walker
A
, Lucio
M
, et al Metabolic functions of gut microbes associate with efficacy of tumor necrosis factor antagonists in patients with inflammatory bowel diseases
. Gastroenterology
. 2019
Nov
;157
(5
):1279
–1292.e11
.
[PubMed]
0016-508545.
Jobin
C
, Sartor
RB
. The I kappa B/NF-kappa B system: a key determinant of mucosalinflammation and protection
. Am J Physiol Cell Physiol
. 2000
Mar
;278
(3
):C451
–62
.
[PubMed]
0363-614346.
Rogler
G
, Brand
K
, Vogl
D
, Page
S
, Hofmeister
R
, Andus
T
, et al Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa
. Gastroenterology
. 1998
Aug
;115
(2
):357
–69
.
[PubMed]
0016-508547.
Inan
MS
, Rasoulpour
RJ
, Yin
L
, Hubbard
AK
, Rosenberg
DW
, Giardina
C
. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line
. Gastroenterology
. 2000
Apr
;118
(4
):724
–34
.
[PubMed]
0016-508548.
Bantel
H
, Berg
C
, Vieth
M
, Stolte
M
, Kruis
W
, Schulze-Osthoff
K
. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis
. Am J Gastroenterol
. 2000
Dec
;95
(12
):3452
–7
.
[PubMed]
0002-927049.
Jobin
C
, Herfarth
HH
, Sartor
RB
. Dexamethasone inhibits TNF alpha gene expression through an I kappa B/NF kappa B pathway in intestinal IEC-6 cells
. Gastroenterology
. 1996
;110
:A333
.0016-508550.
Kaczmarek
N
, Kokot
M
, Makarewicz
A
, Glapa-Nowak
A
, Nowak
JK
, Jamka
M
, et al The therapeutic potential of short-chain fatty acids enemas in inflammatory bowel diseases: a systematic review
. Farm Pol
. 2020
May
;76
(5
):297
–304
. 0014-8261© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
